In response to Covid-19, manufacturers have quickly adapted their commercial approaches. But which of those changes are permanent? What additional capabilities do organizations need to succeed in the “new normal”? What has Covid-19 shown us about weaknesses in the traditional commercial model?

To understand the extent to which the pandemic has accelerated pharmaceutical and medical device manufacturer efforts to reconceptualize their commercial models, Numerof interviewed 60 executives across 36 small, midsize, and large organizations.

Download the qualitative study report to get insight into important topics, including:

  • How many organizations are making permanent changes to their models
  • Types of skills and capabilities that will be required
  • The role virtual detailing will play
  • What leaders believe will be critical to success